Finch Therapeutics Group, Inc. FNCHQ

10.35 0.00 0.00% as of 24 Sep
Market cap
$1.6M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23
P/E ratio
— 0.00 0.00 0.00 0.00 0.00
P/S ratio
— 22.47 22.47 21.07 25.15 9.99
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00
P/Operating CF
— (16.87) (16.87) (28.32) (1.52) (1.65)
P/B ratio
— 0.00 0.00 1.93 0.23 0.27
Price to Tangible BV
— 0.00 0.00 2.12 0.34 0.00
EV/Sales
— 9.79 9.79 14.13 (40.34) 15.97
EV/EBITDA
— 0.00 0.00 0.00 0.32 0.00
EV/Operating CF
— (2.41) (2.41) (3.90) 0.46 (0.31)
EV/FCF
— (2.22) (2.22) (3.15) 0.45 (0.32)
Quick Ratio
— 6.41 8.78 9.06 4.85 6.15
Current Ratio
— 6.64 9.24 9.64 5.08 6.33
Net Debt/EBITDA
— (4.89) 2.53 2.23 0.51 0.31
Debt/Assets
0.00% 132.23% 1.09% 2.17% 8.99% 0.00%
Debt/Equity
— (2.40) 0.01 0.02 0.15 0.00
Asset Turnover
— 0.19 0.06 0.09 0.00 0.00
Operating CF/Net income
— 0.83 0.80 1.15 0.65 0.42
Capex/Depreciation
— 0.00 (3.33) (6.92) (0.40) 0.87
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00
ROE
— 26.74% 50.68% (109.21%) (76.96%) (126.06%)
ROA
— (38.34%) (28.76%) (29.77%) (59.05%) (68.48%)
ROIC
— 0.00% (62.50%) (50.92%) (183.71%) 0.00%
Return on Tangible Assets
— (46.04%) (38.69%) (39.46%) (151.25%) (334.37%)
Average Days of Receivables
— 170.60 51.78 9.73 61.05 0.00
Research and Development Expense of Revenue
— 227.11% 429.38% 309.08% 6,139.72% 6,728.04%
Selling, General and Administrative Expense of Revenue
— 73.26% 181.51% 114.60% 4,203.48% 25,149.53%
Intangible Assets out of Total Assets
0.00 0.47 0.11 0.08 0.20 0.00
Share Based Compensation of Revenue
— 0.00% 40.15% 22.45% 911.03% 1,802.80%
Graham Net Nets
— 0.45 0.45 0.31 0.34 (1.08)
Graham Number
— 0.00 1,073.24 0.00 0.00 0.00
Earnings Yield
— (22.68%) (22.68%) (19.38%) (531.37%) (1,247.91%)
Free Cash Flow Yield
— (19.58%) (19.58%) (21.27%) (355.72%) (492.21%)
Revenue per Share
— 6.31 28.46 14.20 0.54 0.07
Operating CF per Share
— (10.76) (115.52) (51.43) (47.08) (19.63)
Capex per Share
— 0.00 (9.71) (12.20) (1.37) 0.83
Free Cash Flow per Share
— (10.76) (125.23) (63.62) (48.45) (18.80)
Cash per Share
— 26.22 367.66 102.25 44.68 15.65
Shareholders Equity per Share
— (37.00) 506.40 154.91 60.20 14.26
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (37.00) 506.40 154.91 60.20 14.26
Free Cash Flow
— (17.32) (33.96) (83.05) (77.03) (30.18)
Working Capital
— 41.30 94.68 127.76 59.86 21.76
Capital Expenditures
— (1.00) (2.63) (15.92) (2.18) 1.33
Net Current Asset Value
— (119.17) 78.16 119.41 7.32 (6.64)
EV/EBIT
— 0.00 0.00 0.00 0.30 0.00
Capex to Sales
— 0.00 0.34 0.86 2.53 (12.40)
Net Profit Margin
— (204.39%) (509.66%) (313.84%) (13,315.45%) (69,863.55%)
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— 0.13 0.11 0.12 0.35 2.56
Cash ROIC
— (16.77%) (16.05%) (25.48%) (50.05%) (66.86%)
Accounts Receivable Turnover
— 3.48 2.64 23.33 2.70 0.00
Accounts Payable Turnover
— 0.49 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 — — 0.00 —
Average Days of Payables
— 300.35 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 19.72 — — 0.00 —
Average Receivables
— 2.92 2.92 0.79 0.32 —
Average Payables
— 1.64 1.64 3.18 2.42 0.62
Average Assets
— 54.13 136.80 195.35 194.15 109.16
Average Common Equity
— (77.63) (77.63) 53.25 148.97 59.30

Fold the line items

Columns are period end dates